<DOC>
	<DOCNO>NCT00084097</DOCNO>
	<brief_summary>This study evaluate safety usefulness omalizumab ( anti-IgE , Xolair ) reduce eosinophil count improve symptom patient eosinophilic gastroenteritis ( EG ) . EG disorder unknown cause eosinophil , type white blood cell , increase blood gut tissue . Patients EG symptom like stomach pain , bloating , vomit . About 50 percent EG patient food environmental allergy , may play role EG . Some patient EG improve significantly diet avoid food allergic . Immunoglobulin E ( IgE ) antibody play important role initiate allergic reaction . Omalizumab monoclonal antibody direct IgE . The Food Drug Administration approve omalizumab 2003 treat patient 12 year age old allergic asthma . Patients 12 76 year age eosinophilic gastroenteritis blood eosinophil count 500 food allergy allergy inhale allergen may eligible study . Candidates screen medical history , physical examination , blood urine test . Participants undergo follow procedure : - Leukapheresis . This procedure do collect quantity white blood cell study effect omalizumab eosinophil immune substance . Blood flow needle place arm vein catheter ( plastic tube ) machine separate blood component centrifugation ( spin ) . Some white cell remove rest blood ( red cell , plasma platelet ) return body needle arm . - Skin testing . Participants test allergy specific substance . A small amount various allergen ( substance cause allergy ) place subject 's arm . The skin prick site allergen skin reaction several minute observe . - Upper low endoscopy . One procedures do , depend part gastrointestinal tract involve , examine tract . If procedure do , perform time . For upper endoscopy , subject 's throat spray numbing medicine long , flexible tube pass esophagus , stomach small intestine . For low endoscopy , tube pass rectum ...</brief_summary>
	<brief_title>Omalizumab Treat Eosinophilic Gastroenteritis</brief_title>
	<detailed_description>Eosinophilic gastroenteritis ( EG ) characterize eosinophilic infiltration bowel wall , gastrointestinal symptom , 50 % patient , peripheral eosinophilia . Approximately one half EG patient multiple food allergy and/or elevate immunoglobulin E ( IgE ) , suggest allergic etiology . The purpose study evaluate safety efficacy humanize monoclonal anti-IgE antibody , omalizumab ( Xolair ( Registered Trademark ) ) , eosinophilic gastroenteritis . Omalizumab approve use asthma dose subcutaneously base serum total IgE level body weight , maximum dose 375 mg every 2 week . Subjects EG , either food hypersensitivity environmental allergy admit Clinical Center . All subject undergo thorough clinical evaluation , include endoscopy . The primary endpoint evaluation safety omalizumab efficacy reduce peripheral blood absolute eosinophil count . In addition , follow secondary endpoint study : symptom score , study drug pharmacodynamics , tissue eosinophilia . Blood cell serum collect evaluated laboratory address issue related immunopathogenesis treatment EG . This study provide good understand inflammatory allergy mediator pathogenesis EG may provide potential therapy EG . Following subcutaneous administration initial dose omalizumab ( maximum 375 mg ) , subject followed inpatient minimum 24 hour monitor adverse effect . Subsequent dos administer biweekly total 8 dos .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . All Subjects must least 12 year age old 76 year age . 2 . All subject must meet establish diagnostic criterion eosinophilic gastroenteritis : gastrointestinal symptom , histologic evidence gastrointestinal tissue infiltration eosinophils great equal 25 eosinophil per high powered field , know etiology eosinophilia despite careful clinical evaluation . 3 . Eosinophilia great 500/mm3 screening . 4 . Baseline value within follow laboratory range : White blood cell count great equal 3,300 cells/uL Absolute neutrophil count great equal 1,000 cells/uL Hemoglobin great equal 10 g/dL Platelet count great equal 100,000 platelet uL 5 . Evidence atopy define one following : Skin test RAST test Serum IgE great equal to100 6 . Women childbearing potential : negative serum BetahCG . 7 . Agree practice abstinence effective contraception initiation protocol 3 month follow last infusion study drug ( effective contraception method include abstinence , surgical sterilization either partner , barrier method diaphragm , condom , cap , sponge , hormonal contraception ) . 8 . Weight ( Kg ) x serum IgE ( IU/mL ) less equal 63,000 ( per dose restriction ) . 9 . Stable corticosteroid dose one month prior screen willingness continue dose first 16 week study . 10 . Subjects ( guardian young patient ) must able give informed consent ( assent appropriate ) . EXCLUSION CRITERIA : 1 . Pregnant nursing woman . 2 . HIV positive know immunodeficiency . 3 . Use investigational agent within 30 day study . 4 . Presence FIP1PDGFR fusion gene . 5 . Any condition , investigator 's opinion , place patient undue risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>December 23, 2008</verification_date>
	<keyword>Allergy</keyword>
	<keyword>IgE</keyword>
	<keyword>Eosinophil</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Eosinophilic Gastroenteritis</keyword>
	<keyword>EG</keyword>
</DOC>